SCHEMBL20119904

SCHEMBL20119904

Clc1nc(NCc2ccnc3ccccc23)c2nc[nH]c2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.44
PDE5A O76074 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.39
LOXL2 Q9Y4K0 1/20 0.38
ADORA2A P29274 3/20 0.37
ADORA3 P0DMS8 2/20 0.37
ADORA1 P30542 2/20 0.37
HTR1A P08908 2/20 0.37
ADRA1D P25100 2/20 0.37
ADRA1A P35348 2/20 0.37
ADRA1B P35368 2/20 0.37
TMIGD3 P0DMS9 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
EGFR P00533 1/20 0.36
FLT1 P17948 1/20 0.36
KDR P35968 1/20 0.36
LMNA P02545 1/20 0.36
ALOX15 P16050 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119891 0.82 APP (0.48) APPPDE5ALOXL2HTR1AADRA1D
SCHEMBL20119609 0.79 ADORA3 (0.49) SMN1; SMN2ADORA3ADORA1TMIGD3HTR2C
SCHEMBL1216376 0.78 CDK1 (0.55) APPPDE5ASMN1; SMN2TMIGD3HTR2C
SCHEMBL20119597 0.78 LMNA (0.38) SMN1; SMN2ADORA2AADORA3TMIGD3HTR2C
SCHEMBL20119459 0.78 RECQL (0.51) PDE5ASMN1; SMN2TMIGD3HTR2CHTR2B
SCHEMBL20119598 0.76 KCNH3 (0.43) SMN1; SMN2LOXL2ADORA3ADORA1TMIGD3
SCHEMBL20119692 0.76 SMN1; SMN2 (0.34) SMN1; SMN2ADORA2AADORA3ADORA1TMIGD3
SCHEMBL15756676 0.76 TSHR (0.55) SMN1; SMN2ADORA2AADORA3LMNAALOX15
SCHEMBL13906497 0.76 PKM (0.46) SMN1; SMN2LMNA
SCHEMBL20119583 0.75 TMIGD3 (0.43) APPPDE5ASMN1; SMN2TMIGD3HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 APP 604/4885PDE5A 3202/4885SMN1; SMN2 11/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 APP 604/4885PDE5A 3202/4885SMN1; SMN2 11/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 APP 604/4885PDE5A 3202/4885SMN1; SMN2 11/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 APP 604/4885PDE5A 3202/4885SMN1; SMN2 11/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 APP 604/4885PDE5A 3202/4885SMN1; SMN2 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.